grade
pharmaceutical primary standard
API family
phenylalanine
manufacturer/tradename
EDQM
mp
270-275 °C (dec.) (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
N[C@@H](Cc1ccccc1)C(O)=O
InChI
1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m0/s1
InChI key
COLNVLDHVKWLRT-QMMMGPOBSA-N
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Sohei Nakayama et al.
Cancer research, 74(20), 5891-5902 (2014-08-29)
The discovery of somatic mutations in EGFR and development of EGFR tyrosine kinase inhibitors (TKI) have revolutionized treatment for lung cancer. However, resistance to TKIs emerges in almost all patients and currently no effective treatment is available. Here, we show
Christineh N Sarkissian et al.
Molecular genetics and metabolism, 86 Suppl 1, S22-S26 (2005-09-17)
Phenylketonuria (PKU) is an autosomal recessive genetic disorder in which mutations in the phenylalanine-4-hydroxylase (PAH) gene result in an inactive enzyme (PAH, EC 1.14.16.1). The effect is an inability to metabolize phenylalanine (Phe), translating into elevated levels of Phe in
Marte I Flydal et al.
IUBMB life, 65(4), 341-349 (2013-03-05)
Mammalian phenylalanine hydroxylase (PAH) catalyzes the rate-limiting step in the phenylalanine catabolism, consuming about 75% of the phenylalanine input from the diet and protein catabolism under physiological conditions. In humans, mutations in the PAH gene lead to phenylketonuria (PKU), and
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| P1150000 | 04061833813782 |